An endurance athlete knows that to go the distance, one has to plan, strategise and then set the pace. Samina Hamied, 48, third generation heir to Cipla, founded in 1935 by her grandfather Khwaja Abdul Hamied, challenges herself with regular runs and marathons all over the world. Building year-on-year on the legacy, in FY23, the company recorded the highest-ever revenue and EBITDA. Its India business delivered 8 quarters of strong double-digit growth, maintaining market share in key therapy areas across respiratory, urology, anti-infective and cardiac. The U.S. business grew over 23% last year and currently stands at $733 million.
“We recently partnered with Ethris for mRNA-based therapies and have a strong pipeline of in-licensed biosimilars. We are building solutions around the care continuum from easy and early diagnostics to efficient treatment and monitoring, and in line with this, we acquired stake in Achira Labs, which is engaged in the development and commercialisation of point-of-care (PoC) medical test kits in India” says Hamied. Cipla recently introduced Cippoint, a point-of-care testing device that offers a wide range of testing parameters in the Indian market. The company is also focusing on therapies of the future by transforming into a digital organisation to build connections with patients, doctors, and other stakeholders. Cipla Digital Health serves as an enabler of digital for future readiness across functions. — Gina Krishnan